Preclinical rationale for entinostat in embryonal rhabdomyosarcoma

Abstract Background Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in the pediatric cancer population. Survival among metastatic RMS patients has remained dismal yet unimproved for years. We previously identified the class I-specific histone deacetylase inhibitor, entinostat (ENT), as...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Narendra Bharathy, Noah E. Berlow, Eric Wang, Jinu Abraham, Teagan P. Settelmeyer, Jody E. Hooper, Matthew N. Svalina, Zia Bajwa, Martin W. Goros, Brian S. Hernandez, Johannes E. Wolff, Ranadip Pal, Angela M. Davies, Arya Ashok, Darnell Bushby, Maria Mancini, Christopher Noakes, Neal C. Goodwin, Peter Ordentlich, James Keck, Douglas S. Hawkins, Erin R. Rudzinski, Atiya Mansoor, Theodore J. Perkins, Christopher R. Vakoc, Joel E. Michalek, Charles Keller
Formato: Artigo
Idioma:Inglês
Publicado em: BMC 2019-05-01
Colecção:Skeletal Muscle
Assuntos:
Embryonal rhabdomyosarcoma (eRMS)
Entinostat
Vincristine
HDAC3
Patient-derived xenograft (PDX)
Acesso em linha:http://link.springer.com/article/10.1186/s13395-019-0198-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados